Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-01-27

FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental labeling change for INVOKAMET XR, the fixed-dose combination of canagliflozin and metformin hydrochloride from Janssen Pharmaceutica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)

Snippet

SUPPL AP for INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)